At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TVGN Tevogen Bio Holdings
Not Yet Opened 04-30 16:00:00 EDT
6.64
+0.22
+3.43%
盘后6.64
+0.000.00%
17:53 EDT
High6.83Low6.42Vol7.35K
Open6.42D1 Closing6.42Amplitude6.31%
Mkt Cap27.65MTradable Cap7.52MTotal Shares4.16M
T/O48.68KT/O Rate0.65%Tradable Shares1.13M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Tevogen says PredicTcell training nears completion, precision improves about 10%
Reuters  ·  04-27
Tevogen says PredicTcell training nears completion, precision improves about 10%
Tevogen Bio gets Nasdaq notice for failing $50 million market value requirement
Reuters  ·  04-23
Tevogen Bio gets Nasdaq notice for failing $50 million market value requirement
Tevogen Bio FY25 net loss widens to $26.3 million
Reuters  ·  04-01
Tevogen Bio FY25 net loss widens to $26.3 million
BRIEF-Tevogen Advances Strategic CRO Evaluation To Expand Clinical Research Delivery Capabilities And Drive Revenue Growth
Reuters  ·  03-27
BRIEF-Tevogen Advances Strategic CRO Evaluation To Expand Clinical Research Delivery Capabilities And Drive Revenue Growth
Tevogen Bio Holdings: Opportunity Expected to Contribute More Than $20 Mln in Annual Revenue While Supporting Double-Digit Growth Beginning Next Year
THOMSON REUTERS  ·  03-27
Tevogen Bio Holdings: Opportunity Expected to Contribute More Than $20 Mln in Annual Revenue While Supporting Double-Digit Growth Beginning Next Year
Tevogen Advances Strategic Cro Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
THOMSON REUTERS  ·  03-27
Tevogen Advances Strategic Cro Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen Bio implements 1-for-50 reverse stock split; Nasdaq bid-price compliance returns
Reuters  ·  03-26
Tevogen Bio implements 1-for-50 reverse stock split; Nasdaq bid-price compliance returns
Tevogen Bio Regains Compliance With Nasdaq Listing Rule
MT Newswires Live  ·  03-26
Tevogen Bio Regains Compliance With Nasdaq Listing Rule
Tevogen regains compliance with Nasdaq minimum bid price requirement
TIPRANKS  ·  03-26
Tevogen regains compliance with Nasdaq minimum bid price requirement
Tevogen Regains Compliance With Nasdaq Minimum Bid Price Requirement
THOMSON REUTERS  ·  03-26
Tevogen Regains Compliance With Nasdaq Minimum Bid Price Requirement
Tevogen Bio Holdings Inc expected to post a loss of $2.00 a share - Earnings Preview
Reuters  ·  03-24
Tevogen Bio Holdings Inc expected to post a loss of $2.00 a share - Earnings Preview
Tevogen CIO Mittul Mehta to Speak at Microsoft Fabric Community Conference FabCon 2026
Reuters  ·  03-19
Tevogen CIO Mittul Mehta to Speak at Microsoft Fabric Community Conference FabCon 2026
Tevogen Bio Holdings - Lead Investor Confirmed Intention to Maintain Current Shareholdings
THOMSON REUTERS  ·  03-14
Tevogen Bio Holdings - Lead Investor Confirmed Intention to Maintain Current Shareholdings
Tevogen Bio Holdings Inc - Board Continues to Evaluate Potential One-Time Special Cash Dividend
THOMSON REUTERS  ·  03-14
Tevogen Bio Holdings Inc - Board Continues to Evaluate Potential One-Time Special Cash Dividend
Tevogen Bio says it will use no more than 1% of authorized shares over the next 12 months
Reuters  ·  03-14
Tevogen Bio says it will use no more than 1% of authorized shares over the next 12 months
BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio
Reuters  ·  03-14
BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio
BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push
Reuters  ·  03-14
BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push
Tevogen reports performance advancements for Tevogen.AI platform
TIPRANKS  ·  03-14
Tevogen reports performance advancements for Tevogen.AI platform
Tevogen reports PredicTcell Beta recall at 92% and precision at 48%
Reuters  ·  03-14
Tevogen reports PredicTcell Beta recall at 92% and precision at 48%
Tevogen.AI Reports Advancements in Predictcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
THOMSON REUTERS  ·  03-14
Tevogen.AI Reports Advancements in Predictcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
No data available

Introduction

Company Name.
Tevogen Bio Holdings
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Issue price:
--